Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy

Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy

Source: 
Endpoints
snippet: 

Celgene and Bristol Myers Squibb may have combined forces, but their latest mix of multiple myeloma treatments don’t appear to be a good match.

Bristol Myers announced that its Phase III trial combining the BMS drug Empliciti — co-developed with AbbVie — with Celgene’s long-running blockbuster Revlimid had failed. The cocktail did not help first-line patients hold off cancer progression for longer than just Revlimid alone. (Both treatment arms were also given the steroid dexamethasone.)